Management of patients with generalised myasthenia gravis and COVID-19: four case reports

Affiliations

¹ Department of Clinical Neurosciences, University Hospitals Geneva, Geneve, Switzerland annemarie.hubers@hcuge.ch.
² Division of Neurology, University Hospitals of Geneva, Geneva, Switzerland.
³ Department of Clinical Neurosciences, Division of Neurology, Unit of Neuroimmunology and Multiple Sclerosis, University Hospitals Geneva, Geneva, Switzerland.

Comment

Annemarie Hübers et al. J Neurol Neurosurg Psychiatry. 2020 Oct.

. 2020 Oct;91(10):1124-1125.

doi: 10.1136/jnnp-2020-323565. Epub 2020 Jul 10.

¹ Department of Clinical Neurosciences, University Hospitals Geneva, Geneve, Switzerland annemarie.hubers@hcuge.ch.
² Division of Neurology, University Hospitals of Geneva, Geneva, Switzerland.
³ Department of Clinical Neurosciences, Division of Neurology, Unit of Neuroimmunology and Multiple Sclerosis, University Hospitals Geneva, Geneva, Switzerland.

No abstract available

Keywords: immunology; myasthenia; virology.

Conflict of interest statement

Competing interests: None declared.

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.
International MG/COVID-19 Working Group; Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF Jr, Illa I, Mantegazza R, Murai H, Utsugisawa K, Vissing J, Wiendl H, Nowak RJ. International MG/COVID-19 Working Group, et al. J Neurol Sci. 2020 May 15;412:116803. doi: 10.1016/j.jns.2020.116803. Epub 2020 Mar 25. J Neurol Sci. 2020. PMID: 32247193 Free PMC article. No abstract available.